Cibc World Market Inc. increased its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 46.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 223,163 shares of the medical equipment provider’s stock after purchasing an additional 70,621 shares during the period. Cibc World Market Inc.’s holdings in Boston Scientific were worth $9,741,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Boston Scientific in the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA bought a new stake in Boston Scientific in the second quarter valued at $2,156,233,000. Jupiter Topco LLC acquired a new position in Boston Scientific during the second quarter worth $803,357,000. Janus Henderson Group PLC raised its stake in Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after acquiring an additional 3,907,981 shares in the last quarter. Finally, Amundi raised its stake in Boston Scientific by 1.2% during the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after acquiring an additional 173,208 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. downgraded shares of Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 target price on the stock. in a research note on Wednesday, October 28th. Deutsche Bank set a $48.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Thursday, October 29th. Barclays dropped their target price on shares of Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a research report on Friday, October 30th. Evercore cut their price target on shares of Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada reduced their price target on shares of Boston Scientific from $70.00 to $52.00 and set an “outperform” rating on the stock in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.43.
Read Our Latest Research Report on BSX
Boston Scientific Stock Performance
Shares of NYSE:BSX opened at $41.96 on Friday. Boston Scientific Corporation has a twelve month low of $39.57 and a twelve month high of $101.91. The firm has a market cap of $60.82 billion, a PE ratio of 13.70, a price-to-earnings-growth ratio of 1.29 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. The business has a fifty day moving average of $43.83 and a 200-day moving average of $53.26.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the company earned $0.75 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific Corporation will post 3.17 EPS for the current fiscal year.
Boston Scientific Company Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
